# Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

> **NCT01313624** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 266 (actual)

## Conditions studied

- Bronchiectasis

## Interventions

- **DRUG:** AZLI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01313624
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-03
- **Final completion:** 2013-06
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2014-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313624, "Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT01313624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*